TY  - JOUR
AU  - Kähler, K. C.
AU  - Hassel, J. C.
AU  - Ziemer, M.
AU  - Rutkowski, P.
AU  - Meier, F.
AU  - Flatz, L.
AU  - Gaudy-Marqueste, C.
AU  - Zimmer, Laura
AU  - Santinami, M.
AU  - Russano, F.
AU  - von Wasielewski, I.
AU  - Eigentler, T. K.
AU  - Maio, M.
AU  - Zalaudek, I.
AU  - Haferkamp, S.
AU  - Quaglino, P.
AU  - Welzel, J.
AU  - Röcken, C.
AU  - Enk, A.
AU  - Simon, J-C
AU  - Świtaj, T.
AU  - Garzarolli, M.
AU  - Amaral, T.
AU  - Malissen, N.
AU  - Livingstone, E.
AU  - Elia, G.
AU  - Covelli, A.
AU  - Lorizzo, K.
AU  - Neri, D.
AU  - Mulatto, S.
AU  - Parca, A.
AU  - Pizzichi, B.
AU  - Ascierto, P. A.
AU  - Garbe, C.
AU  - Robert, C.
AU  - Schadendorf, D.
AU  - Hauschild, A.
TI  - Neoadjuvant Intralesional Targeted Immunocytokines (Daromun) in Stage III Melanoma.
JO  - Annals of oncology
VL  - nn
SN  - 0923-7534
CY  - Amsterdam [u.a.]
PB  - Elsevier
M1  - DKFZ-2025-01366
SP  - nn
PY  - 2025
N1  - epub
AB  - This phase 3 trial assessed daromun, a combination of two fibronectin-targeting immunocytokines (L19IL2 and L19TNF), as a neoadjuvant treatment for patients with clinically detectable stage IIIB/C melanoma (AJCC version 7).Patients were randomized to 4 weekly intralesional daromun administrations (13 Mio IU of L19IL2 and 400 μg of L19TNF) followed by surgery, or upfront surgery. Pretreatment with approved adjuvant agents was allowed. The primary endpoint was recurrence-free survival (RFS): events were disease recurrence or death from any cause after complete surgical tumor resection.246 patients were randomized and included in the intention-to-treat analysis: 74
KW  - Neoadjuvant (Other)
KW  - immunotherapy (Other)
KW  - intralesional (Other)
KW  - locally advanced (Other)
KW  - melanoma (Other)
KW  - resectable (Other)
KW  - targeted immunocytokines (Other)
LB  - PUB:(DE-HGF)16
C6  - pmid:40633690
DO  - DOI:10.1016/j.annonc.2025.06.014
UR  - https://inrepo02.dkfz.de/record/302826
ER  -